Karuna Therapeutics Aktie [WKN DE: A2PM5N / ISIN: US48576A1007]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Karuna Therapeutics Inc Registered Shs

22.02.24		Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update (Businesswire)
27.12.23		SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONN (PR Newswire)
22.12.23		SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX (PR Newswire)
22.12.23		Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash (RTTNews)
22.12.23		Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics (Businesswire)
15.12.23		Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia (Businesswire)
29.11.23		FDA Accepts New Drug Application For Karuna Therapeutics' KarXT To Treat Schizophrenia (RTTNews)
29.11.23		Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia (Businesswire)
17.11.23		Karuna Announces Positive Results From Phase 1b BP Monitoring Trial Of KarXT In Schizophrenia (RTTNews)
16.11.23		Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia (Businesswire)
02.11.23		Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates (Businesswire)
01.11.23		Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress (Businesswire)
01.11.23		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
19.10.23		Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023 (Businesswire)
04.10.23		Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress (Businesswire)
28.09.23		Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia (Businesswire)
30.08.23		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
03.08.23		Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates (Businesswire)
03.08.23		Karuna Therapeutics Announces Leadership Appointments (Businesswire)
20.07.23		Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023 (Businesswire)
30.05.23		Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (Businesswire)
22.05.23		Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting (Businesswire)
04.05.23		Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates (Businesswire)
02.05.23		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
20.04.23		Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023 (Businesswire)
24.03.23		Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
23.03.23		Karuna Therapeutics to Present at the Stifel 2023 CNS Days (Businesswire)
23.03.23		Royalty Pharma Acquires Interest In PureTech's Royalty In Karuna Therapeutics' KarXT (RTTNews)
22.03.23		Karuna Therapeutics Announces Pricing of Public Offering of Common Stock (Businesswire)
20.03.23		Karuna Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
20.03.23		Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia (Businesswire)
23.02.23		Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates (Businesswire)
09.02.23		Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference (Businesswire)
02.02.23		Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates (Businesswire)
31.01.23		Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer (Businesswire)
03.01.23		Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
06.12.22		Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer (Businesswire)
03.11.22		Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates (Businesswire)
01.11.22		Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference (Businesswire)
06.10.22		Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress (Businesswire)
01.09.22		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
12.08.22		Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
10.08.22		Karuna Therapeutics Announces Pricing of Public Offering of Common Stock (Businesswire)
08.08.22		Karuna Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
08.08.22		Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia (Businesswire)
06.06.22		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
18.05.22		Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease (Businesswire)
05.05.22		Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update (Businesswire)
03.05.22		Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference (Businesswire)
10.03.22		Karuna Therapeutics to Present at Upcoming Investor Conferences (Businesswire)

1 | Weiter

Newssuche

Karuna Therapeutics Peer Group Nachrichten

22.12.23

Karuna Therapeutics-Aktie vorbörslich mit Kurssprung: Bristol-Myers Squibb will Karuna für Milliardenbetrag kaufen - Bristol-Myers-Aktie im Plus

Meistgelesene Nachrichten

Mit Ripple Millionär werden? So klappt’s!

Pierer Mobility-Aktie verliert: Insolvente KTM zahlt Dezember-Gelder doch nicht vorzeitig und stoppt Produktion

Israels Armee: Hamas-Kommandozentrale in Gaza angegriffen

Bitcoin klettert über 107.000 US-Dollar und schafft neues Allzeithoch

Analyst sieht Gründe für noch mehr Optimismus: Bitcoin und Aktienmarkt werden weiter steigen

EZB-Zinsentscheid im Blick: ATX schließt mit Gewinnen -- DAX beendet Handel fester -- US-Märkte letztendlich schwach -- Börsen in Japan und China schließen mit Zuwächsen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	18.12.2024 07:45
Kaufwert:	EUR
	Hinzufügen Speichern